Display options
Cite
Rangamuwa K, Leong T, Bozinovski S, et al. Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation. Transl Lung Cancer Res. 2021;10(6):2858-2864doi: 10.21037/tlcr-21-76.
Rangamuwa, K., Leong, T., Bozinovski, S., Christie, M., John, T., Antippa, P., Irving, L., & Steinfort, D. (2021). Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation. Translational lung cancer research, 10(6), 2858-2864. https://doi.org/10.21037/tlcr-21-76
Rangamuwa, Kanishka, et al. "Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation." Translational lung cancer research vol. 10,6 (2021): 2858-2864. doi: https://doi.org/10.21037/tlcr-21-76
Rangamuwa K, Leong T, Bozinovski S, Christie M, John T, Antippa P, Irving L, Steinfort D. Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation. Transl Lung Cancer Res. 2021 Jun;10(6):2858-2864. doi: 10.21037/tlcr-21-76. PMID: 34295683; PMCID: PMC8264342.
Copy Download .nbib Format: NLM
Share it on

Transl Lung Cancer Res. 2021 Jun;10(6):2858-2864. doi: 10.21037/tlcr-21-76.

Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation.

Translational lung cancer research

Kanishka Rangamuwa, Tracy Leong, Steven Bozinovski, Michael Christie, Thomas John, Phillip Antippa, Louis Irving, Daniel Steinfort

Affiliations

  1. Department of Respiratory Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia.
  2. Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
  3. Department of Respiratory Medicine, Austin Hospital, Heidelberg, Victoria, Australia.
  4. Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
  5. School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
  6. Department of Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
  7. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  8. Department of Thoracic Surgery, Royal Melbourne Hospital, Parkville, Victoria, Australia.

PMID: 34295683 PMCID: PMC8264342 DOI: 10.21037/tlcr-21-76

Abstract

Limited early evidence indicates thermal ablation of non-small cell lung cancer (NSCLC) may induce alterations to the immune response that could enhance the efficacy of immunotherapy with immune checkpoint inhibitor therapy. This study reports pilot data demonstrating increased programmed death-ligand 1 (PD-L1) expression on tumour cells in response to bronchoscopic thermal vapour ablation. Five patients underwent bronchoscopic thermal vapour ablation under a treat-and-resect protocol, as part of a clinical safety and feasibility study, with lobectomy performed five days after thermal vapour ablation. PD-L1 (clone SP263) immunohistochemistry (IHC) tumour proportion score (TPS) was assessed on both baseline diagnostic biopsy specimens, and post-ablation resection specimens in five patients with stage I NSCLC. Two areas of the resection sample defined as viable tumour and injured tumour were examined. All tumours demonstrated 0% PD-L1 TPS at baseline. Three of five (60%) patients demonstrated an increase in PD-L1 TPS in areas of injured tumour to 20%, 30% and 50%. One patient demonstrated an increase in PD-L1 expression in an area of viable tumour to 5%. Changes in PD-L1 expression did not correlate with measures of systemic inflammation. Our findings comprise the first evidence that thermal ablation of NSCLC may induce PD-L1 expression. Further investigation is required to determine the extent of an adaptive immune response, and confirm the potential for augmentation of clinical response to immune check point inhibitor therapy in NSCLC.

2021 Translational Lung Cancer Research. All rights reserved.

Keywords: Non-small cell lung cancer (NSCLC); cancer immunity; programmed death-ligand 1 (PD-L1); thermal ablation

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-21-76). The series “Lung cancer and the immune system” was commissione

References

  1. Lung Cancer. 2019 Jan;127:59-65 - PubMed
  2. Respiration. 2021;100(5):432-442 - PubMed
  3. BMC Cancer. 2020 Dec 3;20(1):1185 - PubMed
  4. Nat Commun. 2020 May 8;11(1):2285 - PubMed
  5. N Engl J Med. 2015 May 21;372(21):2018-28 - PubMed
  6. Cancers (Basel). 2019 Feb 27;11(3): - PubMed
  7. Nat Rev Drug Discov. 2019 Mar;18(3):197-218 - PubMed
  8. Am J Respir Crit Care Med. 2017 Aug 1;196(3):274-282 - PubMed
  9. Sci Rep. 2020 Mar 13;10(1):4677 - PubMed
  10. Cryobiology. 2018 Feb;80:114-118 - PubMed
  11. Semin Thorac Cardiovasc Surg. 2016 Summer;28(2):585-592 - PubMed
  12. Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21 - PubMed
  13. J Thorac Oncol. 2018 Jun;13(6):831-839 - PubMed
  14. Chest. 2013 May;143(5 Suppl):e278S-e313S - PubMed
  15. Clin Cancer Res. 2016 Mar 1;22(5):1173-1184 - PubMed
  16. Clin Lung Cancer. 2018 Jan;19(1):12-16 - PubMed
  17. Sci Adv. 2020 Sep 18;6(38): - PubMed

Publication Types